Who gets Alzheimer's drugs? Race, vulnerability and health status shape access

The first disease-modifying drugs for Alzheimer's disease offer patients the ability to slow cognitive decline by targeting amyloid plaques in the brain. But a new study suggests that not all patients have the same opportunity to receive these treatments.

Read it at Medical Xpress ↗

← Front page